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A combination of electrophysiological and genetic studies has 
resulted  in  the  identification  of  several  skeletal  muscle  disor-
ders  to  be  caused  by  pathologically  functioning  ion  channels 
and  has  led  to  the  term  channelopathies.  Typical  hereditary 
muscle channelopa thies are congenital myasthenic syndromes, 
non-dystrophic myotonias, periodic paralyses, malignant hyper-
thermia, and central core disease. Most muscle channelopathies 
are commonly considered to be benign diseases. However, life-
threatening weakness episodes or progressive permanent weak-
ness may make these diseases severe, particularly the periodic 
paralyses (PP). Even in the typical PP forms characterized by 
episodic occurrence of weakness, up to 60% of the patients suffer 
from permanent weakness and myopathy with age. In addition, 
some PP patients present with a predominant progressive muscle 
weakness phenotype. The weakness can be explained by strongly 
depolarized fibers that take up sodium and water and that are 
electrically inexcitable. Drugs that repolarize the fiber membrane 
can restore muscle strength and may prevent progression. 
Key  words:  Congenital  myasthenic  syndromes,  non-dystrophic 
myotonias, periodic paralyses, susceptibility to malignant hyper-
thermia, central core disease
Introduction
Most muscle channelopathies have similar clinical 
features: typically the symptoms occur as episodes which 
last  from  minutes  to  days  and  show  spontaneous  and 
complete remission and onset in the first or second dec-
ade of life. Frequently the symptoms can be aggravated 
by exercise, rest following physical activity, hormones, 
mental stress, or certain types of food and drugs. Some 
patients show amelioration at the age of 40 or 50 (1). 
Therefore muscle channelopathies are commonly consid-
ered to be benign diseases. However, severe muscle stiff-
ness and transient weakness in some forms of myotonia, 
and  spontaneous  attacks  of  paralysis  in  PP  drastically 
reduce the patient’s ability to perform activities of daily 
living. The inherent danger of cardiac arrhythmia due to 
excessive hypo- or hyperkalemia aggravates the situation 
in these patients. Since patients with muscle channelopa-
thies may not have any interictal features or the weakness 
may be misinterpreted, they are often thought to have had 
a conversion reaction, and this may cause them to suffer 
needlessly. Up to 60% of the periodic paralysis patients 
develop  a  progressive  myopathy  with  age  resembling 
limb girdle dystrophy. For many patients, misdiagnosis 
and disruption of their jobs and of social and family rela-
tionships are even more distressing than physical power-
lessness. Therefore correct diagnosis including molecular 
genetic  confirmation  and  proper  treatment  are  manda-
tory. This article deals with the various hereditary muscle 
channelopthies such as congenital myasthenic syndromes, 
non-dystrophic myotonias, periodic paralyses, malignant 
hyperthermia, and central core disease. The responsible 
genes, the disease pathogenesis and the therapeutical op-
tions are described (Table 1). 
Congenital myasthenic syndromes –   
not always congenital 
Congenital myasthenic syndromes (CMS) are a het-
erogeneous group of inherited disorders with defective 
transmission  of  neuromuscular  excitation  resulting  in 
muscle fatigue. Weakness is usually evident at birth or 
within the first year or two of life, and is characterized 
by feeding difficulties, ptosis, impaired eye movements, 
and delayed motor milestones. Strength sometimes im-
proves during adolescence, and does not exhibit a pro-
gressive course. Reflexes are usually brisk and muscle 
wasting does not occur. CMS can lead to congenital ar-
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throgryposis multiplex involving reduced fetal movement 
and multiple joint contractures in the neonate. Electromy-
ography in CMS patients reveals a characteristic decre-
ment of compound action potential (CMAP) amplitude 
on repetitive stimulation (3 Hz). The decrement usually 
starts at the second, rarely at the third CMAP, and ends 
at the 4th or 5th. After that, the decrement either improves 
or remains the same. The reduced transmission is usually 
improved by edrophonium. Single fibre recordings show 
an increased variability in the synaptic transmission time 
(“jitter”) and transmission blocks. 
Presynaptic, synaptic, and postsynaptic loss-of-function 
proteins
CMS result from defects in presynaptic, synaptic, and 
postsynaptic proteins. Presynaptic defects reduce acetyl-
choline release and resynthesis due to mutations in the 
choline acetyltransferase gene (CHAT). Synaptic CMS 
are  caused  by  acetylcholinesterase  (AChE)  deficiency 
due to mutations in the COLQ gene encoding the col-
lagenic tail subunit that mediates AChE insertion into the 
synaptic basal lamina. Postsynaptic CMS are caused by 
dominant or recessive mutations in the CHRNA1/B1/D/E 
genes for the nicotinic acetylcholine receptor subunits. 
Loss-of-function mutations, most frequently of CHRNE, 
lead to compensatory expression of fetal δ subunits yield-
ing nicotinic acetylcholine receptor complexes which dif-
fer functionally from the adult type (2). Therefore pro-
teins that anchor or stabilize these subunits are targets 
for  CMS (3, 4).  Mutations  in  the  corresponding  genes 
RAPSN, MUSK and DOK7 are similarly frequent and 
together as frequent as CHRNE mutations. DOK7 and 
COLQ mutations should be considered in patients pre-
senting with proximal weakness and waddling gait and 
Table 1. Overview of hereditary muscle channelopathies.
Disease Gene Protein Inheritance Mutation Therapy
Congenital myasthenic 
syndrome
CHAT Ch-A-T^ recessive loss AChE-I, DAP
COLQ AChE recessive avoid AChE-I
CHRNA-E nAChR domin./rec. gain or loss AChE-I, DAP°
RAPSN rapsyn recessive loss AChE-I, DAP
MUSK MuSK recessive
SCN4A Nav1.4 recessive
DOK7 Dok-7 recessive ephedrin, albuterol
Thomsen myotonia CLCN1 ClC1 dominant loss propafenone,  
flecainide,  
acetazolamide
Becker myotonia recessive loss
Potassium-aggravated 
myotonia







gain (ω-pore) (K), CAI, AA
Hypokalemic periodic 
paralysis 2
gain (ω-pore) K, CAI, AA
Hypokalemic periodic 
paralysis 1
CACNA1S Cav1.1 dominant gain (ω-pore) K, CAI, AA
Thyrotoxic periodic 
paralysis*
KCNJ18 Kir2.18 dominant loss symptomatic
Andersen-Tawil syndrome KCNJ2 Kir2.1 dominant loss CAI
Malignant hyperthermia* CACNA1S Cav1.1 dominant gain dantrolene (crisis)
RYR1 RyR1 dominant gain dantrolene (crisis)
Central core disease domin./rec. gain or loss exercise
Multiminicore disease recessive loss exercise
° AChE-I and DAP to be avoided in the slow-channel syndrome, * Susceptibility, AChE-I = Acetylcholine-esterase inhibitor, DAP = 
3,4-Diaminopyridine, HCT = Hydrochlorothiazide, K = Potassium, CAI = Carbo-anhydrase inhibitor, AA = Aldosterone antagonists, 
^ Cholin-acetyl-transferase, Nav = voltage-gated sodium channelState of the art in hereditary muscle channelopathies
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inward rotation of the knees, even in the absence of symp-
toms suggesting a possible myasthenia (5). Late onset of 
symptoms may occur for RAPSN and DOK7 mutations 
and in the slow-channel syndrome. 
“Kinetic” gain- and loss-of-function nicotinic 
acetylcholine receptor mutations
Rarely, postsynaptic CMS are caused by mutations 
at different sites and different functional domains that 
alter the kinetic channel properties. These kinetic muta-
tions result in the slow- or fast-channel syndromes. The 
low-affinity,  fast  channel  syndrome  is  caused  by  loss-
of-function AChR  subunit  mutations  that  have  similar 
effects as AChR deficiency. Mutations at different sites 
lead to fewer and shorter channel activations. In contrast 
to all above CMS, the slow-channel syndrome presents 
in childhood, adolescence or adult life with upper limb 
predominance  and  contractures,  does  not  respond  to 
acetyl-cholinesterase inhibitors, and is progressive. CMS 
patients with a slow-channel syndrome show increased 
synaptic response to Ach, i.e. characteristic repetitive dis-
charges in response to a single supramaximal stimulus. 
The syndrome results from gain-of-function mutations in 
the ion-conducting pore M2. The leaky AChR exert an 
excitotoxic effect and cause endplate myopathy via focal 
caspase activation. 
Myotonia – plasmalemmal 
hyperexcitability due to mutant 
Na+ or Cl- channels
Muscle stiffness, termed myotonia, ameliorates by 
exercise, the “warm-up phenomenon”, and can be associ-
ated with transient weakness during strenuous muscle ac-
tivity On the contrary, paradoxical myotonia (also called 
paramyotonia) worsens with cold and after exercise. Both 
myotonia and paramyotonia derive from uncontrolled re-
petitive action potentials of the sarcolemma following an 
initial voluntary activation. This may be noted as a myo-
tonic burst in the electromyogram. The involuntary elec-
trical activity prevents the muscle from immediate relax-
ation after contraction, which the patients subsequently 
experience as muscle stiffness. 
As in myasthenia gravis and the CMS, a CMAP dec-
rement can occur at repetitive nerve stimulation at 3 Hz. 
In contrast to the CMS, it starts later and might be more 
pronounced (6, 7). It is caused by the increasing hypoex-
citability of the muscle fiber membrane due to sustained 
membrane depolarization which is not improved by edro-
phonium. This decrement leads to a dramatic loss of iso-
metric muscle strength during the first strong contractions 
after rest. With repeated contractions, CMAP amplitude 
and strength return. This transient weakness occurs in the 
Becker myotonia (Fig. 1) in which the stiffness is usually 
more pronounced than in the Thomsen type. 
Chloride channel myotonias: Thomsen and Becker
Dominant Thomsen and recessive Becker myotonia 
are caused by missense and nonsense mutations in the ho-
modimeric Cl- channel encoded by CLCN1. Functionally, 
the dominant mutants exert a dominant negative effect on 
the dimeric channel complex as shown by co-expression 
studies, meaning that mutant/mutant and mutant/wildtype 
complexes are malfunctional. The most common feature of 
the resulting Cl- currents is a shift of the activation thresh-
old towards more positive membrane potentials almost out 
of the physiological range. As a consequence of this, the 
Cl- conductance is drastically reduced in the vicinity of the 
resting membrane potential. The recessive mutants that do 
not functionally hinder the associated subunit supply the 
explanation of why two mutant alleles are required to re-
duce Cl- conductance sufficiently for myotonia to develop 
in Becker myotonia. 
Sodium channel myotonia and paramyotonia congenita 
(PMC)
In Na+ channel myotonia and paramyotonia, there is a 
gating defect of the Na+ channels destabilizing the inacti-
vated state such that channel inactivation may be slowed 
or incomplete (8-10). This results in an increased tendency 
of the muscle fibers to depolarize which generates repeti-
tive  action  potentials  (myotonia).  The  mutant  channels 
produce a dominant gain of function on the channel as 
well as on cell excitability (Fig. 2). 
One hot spot for the PMC mutations is a special volt-
age-sensing transmembrane region that couples channel 
inactivation to channel activation; another hot spot is an 
intracellular protein loop containing the inactivation par-
ticle (Fig. 3). The potassium-aggravated myotonia (PAM) 
mutations are found in intracellular regions of the protein, 
Figure 1. Transient weakness in a patient with recessive 
myotonia congenita. 
Upper trace: surface EMG recorded over biceps brachii mus-
cle. Lower trace: Concurrent isometric force generated by elbow 
flexors. Note ~5-6 s of diminished electrical and force activity 
followed by gradual recovery. N, Newton [from Lehmann-Horn 
et al., 2004 (1), mod.].K. Jurkat-Rott, F. Lehmann-Horn
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potentially interfering with the channel inactivation proc-
ess. Corresponding to the severity of the disruption of the 
inactivation gate structure on the protein level, there are 
three clinical severities to be distinguished: 1) myotonia 
fluctuans where patients may not be aware of their dis-
order;  2) myotonia  responsive  to  acetazolamide  with  a 
Thomsen-like clinical phenotype, and 3) myotonia per-
manens with continuous electrical myotonia leading to a 
generalized muscle hypertrophy including facial and neck 
muscles  suggestive  of  facial  dysmorphia (11-13). In  all 
three types, body exertion or administration of depolariz-
ing agents may result in a severe or even life-threatening 
myotonic crisis (1). 
As  PMC  channels  fail  to  inactivate  completely  in 
cold environment, the sodium inward current causes an 
intracellular sodium and water accumulation that can be 
visualized in vivo by 23Na- und 1H-MRI (14). Figure 2. Currents through the central pore of normal 
and mutant Nav1.4 channels. 
Macroscopic (A, C) and single-channel (B, D) sodium currents 
of normal and mutant Nav1.4 channels are shown. The currents 
were elicited by a depolarization step from a holding potential of 
-120 mV to +30 mV. Re-openings were more frequent for mutant 
channels, thereby leading to a small persistent current as veri-
fied by the tail current at the end of the pulse (C) [from Lehmann-
Horn et al., 2004 (1), mod.].
Figure 3. The voltage-gated sodium channel of skeletal muscle, NaV1.4. 
The alpha-subunit is composed of 4 highly homologous repeats (I-IV) each consisting of 6 transmembrane segments (S1-S6). When 
inserted in membrane, the 4 repeats of the protein fold to generate a central pore, whereby the S5-S6 loops form the ion-selective 
pore. The S4 segments contain positively charged residues conferring voltage dependence to the protein. Repeats are connected 
by intracellular loops; one of them, the III-IV linker, contains the inactivation particle of the channel. The sketch gives an overview of 
locations of known NaV1.4-mutations [from Jurkat-Rott, et al. 2010 (32) mod.].State of the art in hereditary muscle channelopathies
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Periodic paralysis - plasmalemmal 
hypoexcitability due to mutant Na+ 
or Ca2+ channels
Symptoms occur episodically with varying intervals 
of  normal  muscle  function  and  excitation  because  ion 
channel defects are usually well-compensated and an ad-
ditional trigger is often required for muscle inexcitability 
due to sustained membrane depolarization. This depo-
larization is responsible for the late CMAP decrement at 
repetitive nerve stimulation at 3 Hz (long-exercise test). It 
is not improved by edrophonium. 
Three dominant episodic types of weakness with or 
without myotonia are distinguished by the serum K+ level 
during the attacks of tetraplegia: hyper-, normo- and hy-
pokalemic periodic paralysis (PP). Intake of K+ and glu-
cose has opposite effects in the two disorders: while K+ 
triggers a hyperkalemic attack and glucose is a remedy, 
glucose provokes hypokalemic attacks which are amelio-
rated by K+ intake. Due to additional release of K+ from 
hyperkalemic PP muscle and uptake of K+ into hypoka-
lemic PP muscle, dyskalemia can be that severe during a 
paralytic attack that cardiac complications arise. During 
an attack, death can also occur due to respiratory insuf-
ficiency. 
Hyperkalemic periodic paralysis - Na+ channel paralysis 
combined with myotonia
Most Nav1.4 mutations that cause hyperkalemic PP 
(HyperPP) are situated at inner parts of the transmem-
brane segments or in intracellular protein loops (Fig. 3) 
and affect structures that form the docking site for the 
fast inactivation particle. Thereby, they impair fast chan-
nel inactivation and lead to a persistent Na+ current. At the 
beginning of an attack, the sustained inward current is as-
sociated with a mild membrane depolarization and leads 
to myotonia. The progressing attack is characterized by 
membrane inexcitability and muscle weakness since the 
penetrated Na+ ions go along with a more severe sustained 
membrane depolarization that inactivates most Na+ chan-
nels. Dependent on the location of the underlying muta-
tion, symptoms typical of HyperPP, K+-aggravated myo-
tonia, and paramyotonia congenita can overlap in a given 
patient (15). As in PMC, HyperPP channels fail to inacti-
vate completely, and the sodium inward current causes an 
intracellular sodium and water accumulation that can be 
visualized in vivo by 23Na- und 1H-MRI (14).
Hypokalemic periodic paralysis – caused by Na+  
and Ca2+ channel outer S4 mutations
Hypokalemic PP (HypoPP) differs from the hyperka-
lemic form in the sense that a spontaneous attack is asso-
ciated with hypokalemia, potassium is a remedy, whereas 
carbohydrate- and sodium-rich food triggers an attack. In 
general, the attacks last longer and are more severe. Usu-
ally, the patients are weakest during the second half of 
the night and in the morning, and become stronger as the 
day goes by. 
HypoPP is caused by mutations in two voltage-gated 
cation channels in skeletal muscle Cav1.1 (HypoPP-1) 
and Nav1.4 (HypoPP-2) (Fig. 3) (16). Almost all muta-
tions neutralize a positively charged amino acid in one 
of the outermost arginines or lysines of a voltage sensor. 
The Nav1.4 mutations are situated in the voltage sensors 
of repeats I, II and III. The electrophysiological charac-
terization of the gating defects induced by these muta-
tions revealed a loss of channel function, which does not 
explain the phenotype. By expressing HypoPP mutations 
in Xenopus oocytes, a cation leak was discovered that 
showed the typical characteristics found for the ω-current 
in Shaker K+-channels (17-19). The ω-current, so called 
to differentiate it from the (ω-)current through the ion-
conducting pore, is a hyperpolarization-activated current 
of monovalent cations that is though to flow through the 
S4 gating pore (Fig. 4). The ω-current counteracts the rec-
tifying K+ currents and therefore depolarizes and destabi-
lizes the resting membrane potential so that the fraction of 
depolarized, inexcitable fibers is increased (20). In vivo, 
the muscles from these patients exhibited an intracellular 
sodium accumulation and edema (21).
As muscle fibers with a severe voltage sensor muta-
tion are depolarized not only during hypokalemia but also 
at potassium levels in the normal range, this membrane 
leak might not only explain episodes of weakness, but 
interictal (permanent) weakness as well. The permanent 
weakness associated with a fatty replacement myopathy 
is very frequently found in patients harboring DIV muta-
tions in the calcium channel, i.e. Cav1.1 R1239H (21).
Normokalemic periodic paralysis – caused by Na+ 
channel inner S4 mutations
The term normokalemic PP was originally given to 
a variant described in the 1960s. The disorder resembled 
hyperkalemic PP in many aspects; the only real differenc-
es were the lack of increase in the concentration of serum 
potassium even during serious attacks, and the lack of a 
beneficial effect of glucose administration (1). Recently, 
a  potassium-sensitive  type  of  periodic  paralysis  with 
normokalemia and episodes of weakness reminiscent of 
those in both hyperkalemic (initiation of an attack by po-
tassium) and hypokalamic forms (duration of attacks) was 
reported (22). This phenotype, is caused by SCN4A muta-
tions at deeper locations of the voltage sensor of domain 
II at codon 675. Functionally, R675 mutations generate an 
ω-current with a reversed voltage dependence compared K. Jurkat-Rott, F. Lehmann-Horn
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to mutations causing HypoPP-2, since this site is exposed 
to the extracellular space at stronger depolarizations (23). 
The diagnostics for NormoPP are as described for the two 
more common forms of the disease. The therapy consists 
of avoidance of both hypokalemia and hyperkalemia and 
the administration of acetazolamide. 
K+ channel periodic paralysis with cardiac arrhythmia
Patients with Andersen-Tawil syndrome may experi-
ence a life-threatening ventricular arrhythmia independ-
ent of their PP is the primary cardiac manifestation. The 
syndrome is characterized by the highly variable clinical 
triad of dyskalemic PP, ventricular ectopy, and potential 
dysmorphic features (24). The paralytic attack may be hy-
perkalemic or hypokalemic and accordingly, the response 
to oral K+ is unpredictable. Mutations of the Kir2.1 K+ 
channel, an inward rectifier expressed in skeletal and car-
diac muscle, are causative of the disorder. Kir2.1 channels 
are essential for maintaining the highly negative resting 
membrane potential of muscle fibers and accelerating the 
repolarization phase of the cardiac action potential. The 
mutations mediate loss of channel function by haploinsuf-
ficiency or by dominant-negative effects on the wildtype 
allele and may lead to long-lasting depolarization, fiber 
membrane inexcitability and paralysis. 
Muscle channelopathies due  
to an altered excitation-
contraction coupling 
Muscle contractures, i.e. electrically silent contrac-
tions due to intracellular Ca2+ exceeding the mechanical 
threshold, as well as flaccid weakness are characteris-
tic  features  of  disturbed  muscle  excitation-contraction 
coupling. Two allelic forms are well studied: malignant 
hyperthermia (MH) and central core disease (CCD).
Malignant hyperthermia
Susceptibility to MH is an autosomal dominant pre-
disposition to respond abnormally when exposed to vola-
tile anesthetics, depolarizing muscle relaxants or extreme 
physical activity in hot environments. During exposure 
to  triggering  agents,  a  pathologically  high  increase  in 
myoplasmic Ca2+ concentration leads to increased mus-
cle metabolism and heat production resulting in muscle 
contractures,  hyperthermia  associated  with  metabolic 
acidosis, hyperkalemia, and hypoxia. The metabolic al-
terations usually progress rapidly and without immediate 
treatment, up to 70% of the patients die. Early admin-
istration of dantrolene, an inhibitor of Ca2+ release from 
the sarcoplasmic reticulum (SR) has successfully aborted 
numerous fulminant crises and has reduced the mortality 
rate to less than 10%. 
In most families, mutations can be found in the gene 
encoding the skeletal muscle ryanodine receptor, RyR1. 
This Ca2+ channel is not voltage-dependent on its own, but 
exists under the control of Cav1.1. MHS mutations are usu-
ally situated in the cytosolic part of the protein and show 
gain-of-function effects: they increase RYR1 sensitivity to 
caffeine and other activators as shown in functional tests 
of both excised muscle, isolated native proteins, and ry-
anodine receptors expressed in muscle and non-muscle 
cells. For another MH locus on chromosome 1q31-32, 
an  R1086H  disease-causing  mutation  was  identified  in 
the skeletal muscle L-type calcium channel alpha1 subu-
nit. The mutation is located in an intracellular loop of the 
protein whose functional significance for EC coupling is 
under debate. Although mutations in the same gene cause 
hypokalemic periodic paralysis type 1 this disorder is not 
thought to be associated to MH susceptibility. 
Figure 4.  Leak currents through mutant voltage sensors. 
(A) A replacement of the outermost arginine (left) by a smaller 
amino acid e.g. glycine (center), opens a conductive pathway 
at hyperpolarized potentials, resulting in an inward cation cur-
rent (arrow). At depolarized potentials at which the S4 segment 
moves outward (right), the conductive pathway is closed and the 
cation current ceases. (B) Schematic of cation currents through 
sodium  channels  carrying  charge-neutralizing  substitutions  in 
S4 voltage sensors. Note the large inward current in the hyper-
polarized potential range corresponding to the resting state of 
the leaky S4 voltage sensor [from Jurkat-Rott, et al. 2010 (32) 
mod.].State of the art in hereditary muscle channelopathies
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Central core disease (CCD) and multiminicore disease 
(MmD)
CCD is a mainly dominant congenital myopathy. Al-
though it is genetically heterogeneous, most patients har-
bour a RYR1 mutation (25). It is clinically characterized 
by muscle hypotrophy and weakness and a floppy infant 
syndrome,  often  alongside  other  skeletal  abnormalities 
such as hip displacement and scoliosis. Pathognomonic is 
the abundance of central cores devoid of oxidative enzyme 
activity along the predominant type 1 muscle fibers. Most 
RyR1 mutations are situated in the SR-luminal region. 
Some decrease the open probability of the RyR1 channel 
so that it loses the ability to release Ca2+ in response to the 
conformational DHPR alteration that is induced by de-
polarization of the plasma membrane.26 However, RyR1 
retains the ability to influence the open probability of the 
DHPR. Other mutations increase the open probability of 
the RyR1 channel, leading to depleted SR Ca2+ stores and 
weakness. 
MmD is recessively inherited and genetically hetero-
geneous (27). The moderate form with generalized mus-
cle  weakness  predominantly  of  the  pelvic  girdle,  hand 
involvement, amyotrophy, and hyperlaxity is often associ-
ated with RYR1 mutations. In contrast to CCD, the cores 
are usually multiple, poorly defined and do not extend 
along the whole fiber. 
Medication of muscle 
channelopathies
In  many  CMS,  acetylcholineesterase  inhibitors 
(AChE-I) and 3,4-diaminopyridine (3,4-DAP) are effective 
on the short- and long-term. In the AChE-deficiency and 
the slow-channel syndrome, inhibitors have to be avoided. 
In the latter, fluoxetine is very effective. In CMS caused 
by DOK7 mutations, edrophonium might be successful, 
whereas AChE-I are not effective on the long-term. How-
ever these patients respond to ephedrine and albuterol. 
The aim of drug therapy in myotonia and paramyo-
tonia is to reduce the unvoluntary action potential bursts 
without blocking voluntary high-frequency muscle stim-
ulation.  Local  anesthetics  and  anti-arrhythmic  drugs  of 
class IB or IC effectively relieve stiffness in chloride and 
sodium channel myotonia and prevent weakness occurring 
in PMC with cooling. Agents such as mexiletine (unfor-
tunately taken from the market because of profit shrink-
age) and other lidocaine analogs and the IC antiarrhythmic 
drugs flecainide and propafenone, prevent repetitive firing 
of action potentials due to their “use dependence”, a de-
pendence of the depth of block on the frequency of ac-
tion potentials. The degree of use dependence varies with 
the structure (charge and hydrophobicity) of the drug. 
Beyond this “unspecific” antimyotonic effect, the agents 
seem to be more effective on certain mutant sodium chan-
nels than on normal channels. Particularly mutant sodium 
channels that exhibit an enhanced closed-state inactiva-
tion are sensitive which suggests potential for mutation-
specific treatment (28, 29). Recently relief from episodic 
weakness with pyridostigmine was reported for a PMC 
family (30). However it should be kept in mind that pyri-
dostigmine can exacerbate myotonia. 
Unfortunately  the  spontaneous  and  potassium-in-
duced  attacks  of  weakness  typical  for  HyperPP  and 
also occurring in some PMC patients are not improved 
by lidocaine analogs or antiarrhythmic drugs. However 
diuretics such as hydrochloro  thiazide and acetazolamide 
can decrease frequency and severity of paralytic episodes, 
probably by lowering serum potassium and perhaps by 
shifting the pH to lower values. 
In HypoPP, acute weakness spells can be treated by 
potassium and be prevented by certain carbonic anhydrase 
inhibitors, aldosterone antagonists, and potassium-spar-
ing diuretics. Serum potassium levels in the high normal 
range help reduce the paradoxical membrane depolari-
zation and therefore shift the resting potential to more 
normal values. Acetazolamide also lowers intracellular 
sodium accumulation in these patients addressing both 
pathogenetic factors in HypoPP: depolarization and so-
dium accumulation (21). The repolarizing effect of aceta-
zolamide may be explained at least partially by opening 
of big conductance potassium channels (31).
During  a  malignant  hyperthermia  crisis,  sufficient 
amounts of the antidote dantrolene have to be adminis-
tered intravenously in addition to symptomatic treatment 
such as the immediate stop of the triggering agents. In 
CCD, muscle strength can be improved by exercise (un-
published observation). 
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